Cargando…

Development of an immune-related prognostic biomarker for triple-negative breast cancer

Purpose: Oncology studies employing digital dissection methodologies have provided some insight on the biological features of tumor microenvironment of Triple-negative breast cancer (TNBC), but molecular diagnostics rarely have therapeutic impact. We aimed to identify a novel prognostic biomarker to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yan, Wang, Quan, Yang, Wei-Kang, Wang, Yong-Si, Zhou, Qiao, Lin, Jie, Wei, Xu-Xuan, Liang, Tian, Liu, Tongtong, Fan, Wen-Tao, Liang, Li, Xu, You-Nian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068007/
https://www.ncbi.nlm.nih.gov/pubmed/35481432
http://dx.doi.org/10.1080/07853890.2022.2067894
_version_ 1784700136576778240
author Zhang, Yan
Wang, Quan
Yang, Wei-Kang
Wang, Yong-Si
Zhou, Qiao
Lin, Jie
Wei, Xu-Xuan
Liang, Tian
Liu, Tongtong
Fan, Wen-Tao
Liang, Li
Xu, You-Nian
author_facet Zhang, Yan
Wang, Quan
Yang, Wei-Kang
Wang, Yong-Si
Zhou, Qiao
Lin, Jie
Wei, Xu-Xuan
Liang, Tian
Liu, Tongtong
Fan, Wen-Tao
Liang, Li
Xu, You-Nian
author_sort Zhang, Yan
collection PubMed
description Purpose: Oncology studies employing digital dissection methodologies have provided some insight on the biological features of tumor microenvironment of Triple-negative breast cancer (TNBC), but molecular diagnostics rarely have therapeutic impact. We aimed to identify a novel prognostic biomarker to investigate immune characteristics of TNBC using transcriptomic features. Patients and Methods: We extracted whole transcriptome from breast cancer tissue of 30 TNBC patients and then used bioinformatics approaches to characterize the different immune cell contents in tumor tissue and para-cancerous tissue. We extract 2 indicators to describe the major differences in immune infiltration in the microenvironment between tumor tissue and para-cancerous tissue. We then combined the 2 indicators that represent the levels of increased and decreased infiltration in each sample to obtain the Immune Infiltration Score (IIS). Then we compared the tumor-infiltrating immune cell contents and immune infiltrating status in TNBC samples with CIBERSORT and ESTIMATE score to validate the IIS. Finally, 132 TNBC patients from the Cancer Genome Atlas program (TCGA) dataset was used to validate the predictive power of IIS. Results: 4 types of upregulated and 4 types of downregulated immune cells were identified in the tumor tissue samples of the TNBC patients. Then we developed a novel biomarker, IIS. Results showed that IIS score can clearly separate cancer and para-cancerous tissue. Using the same cutoff value of 0 in the TNBC-TCGA cohort, we show that those patients with a higher IIS had significantly higher PD-L1 expression and shorter progression-free survival time than those with a lower IIS value, indicating IIS score can be generalized to other TNBC datasets. Conclusion: we explored the immune infiltration landscape in 30 TNBC patients and provided IIS as a novel and reliable biomarker to evaluate the progression-free survival and prognosis of the TNBC patients.
format Online
Article
Text
id pubmed-9068007
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-90680072022-05-05 Development of an immune-related prognostic biomarker for triple-negative breast cancer Zhang, Yan Wang, Quan Yang, Wei-Kang Wang, Yong-Si Zhou, Qiao Lin, Jie Wei, Xu-Xuan Liang, Tian Liu, Tongtong Fan, Wen-Tao Liang, Li Xu, You-Nian Ann Med Clinical Pathology Purpose: Oncology studies employing digital dissection methodologies have provided some insight on the biological features of tumor microenvironment of Triple-negative breast cancer (TNBC), but molecular diagnostics rarely have therapeutic impact. We aimed to identify a novel prognostic biomarker to investigate immune characteristics of TNBC using transcriptomic features. Patients and Methods: We extracted whole transcriptome from breast cancer tissue of 30 TNBC patients and then used bioinformatics approaches to characterize the different immune cell contents in tumor tissue and para-cancerous tissue. We extract 2 indicators to describe the major differences in immune infiltration in the microenvironment between tumor tissue and para-cancerous tissue. We then combined the 2 indicators that represent the levels of increased and decreased infiltration in each sample to obtain the Immune Infiltration Score (IIS). Then we compared the tumor-infiltrating immune cell contents and immune infiltrating status in TNBC samples with CIBERSORT and ESTIMATE score to validate the IIS. Finally, 132 TNBC patients from the Cancer Genome Atlas program (TCGA) dataset was used to validate the predictive power of IIS. Results: 4 types of upregulated and 4 types of downregulated immune cells were identified in the tumor tissue samples of the TNBC patients. Then we developed a novel biomarker, IIS. Results showed that IIS score can clearly separate cancer and para-cancerous tissue. Using the same cutoff value of 0 in the TNBC-TCGA cohort, we show that those patients with a higher IIS had significantly higher PD-L1 expression and shorter progression-free survival time than those with a lower IIS value, indicating IIS score can be generalized to other TNBC datasets. Conclusion: we explored the immune infiltration landscape in 30 TNBC patients and provided IIS as a novel and reliable biomarker to evaluate the progression-free survival and prognosis of the TNBC patients. Taylor & Francis 2022-04-28 /pmc/articles/PMC9068007/ /pubmed/35481432 http://dx.doi.org/10.1080/07853890.2022.2067894 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Pathology
Zhang, Yan
Wang, Quan
Yang, Wei-Kang
Wang, Yong-Si
Zhou, Qiao
Lin, Jie
Wei, Xu-Xuan
Liang, Tian
Liu, Tongtong
Fan, Wen-Tao
Liang, Li
Xu, You-Nian
Development of an immune-related prognostic biomarker for triple-negative breast cancer
title Development of an immune-related prognostic biomarker for triple-negative breast cancer
title_full Development of an immune-related prognostic biomarker for triple-negative breast cancer
title_fullStr Development of an immune-related prognostic biomarker for triple-negative breast cancer
title_full_unstemmed Development of an immune-related prognostic biomarker for triple-negative breast cancer
title_short Development of an immune-related prognostic biomarker for triple-negative breast cancer
title_sort development of an immune-related prognostic biomarker for triple-negative breast cancer
topic Clinical Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068007/
https://www.ncbi.nlm.nih.gov/pubmed/35481432
http://dx.doi.org/10.1080/07853890.2022.2067894
work_keys_str_mv AT zhangyan developmentofanimmunerelatedprognosticbiomarkerfortriplenegativebreastcancer
AT wangquan developmentofanimmunerelatedprognosticbiomarkerfortriplenegativebreastcancer
AT yangweikang developmentofanimmunerelatedprognosticbiomarkerfortriplenegativebreastcancer
AT wangyongsi developmentofanimmunerelatedprognosticbiomarkerfortriplenegativebreastcancer
AT zhouqiao developmentofanimmunerelatedprognosticbiomarkerfortriplenegativebreastcancer
AT linjie developmentofanimmunerelatedprognosticbiomarkerfortriplenegativebreastcancer
AT weixuxuan developmentofanimmunerelatedprognosticbiomarkerfortriplenegativebreastcancer
AT liangtian developmentofanimmunerelatedprognosticbiomarkerfortriplenegativebreastcancer
AT liutongtong developmentofanimmunerelatedprognosticbiomarkerfortriplenegativebreastcancer
AT fanwentao developmentofanimmunerelatedprognosticbiomarkerfortriplenegativebreastcancer
AT liangli developmentofanimmunerelatedprognosticbiomarkerfortriplenegativebreastcancer
AT xuyounian developmentofanimmunerelatedprognosticbiomarkerfortriplenegativebreastcancer